^
Association details:
| Biomarker: | CD74-ROS1 F2004L + PD-L1 expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
Published date:
02/08/2021
Excerpt:
A second NGS assay found a possible resistance mutation of c.6012T>G (p.F2004L)...repeat biopsy tissue sample from the supraclavicular lymph node showed that the expression of PD-L1 in both tumor cells and immune cells was 10%...lorlatinib, which is potent for brain metastases, was administered to the patient (100 mg orally once a day)....previously enlarged lymph nodes also shrank to normal size. The patient continued to take lorlatinib and has not experienced disease progression so far...
DOI:
10.1136/jitc-2020-001967
